Skip to main content

Table 3 EGFR status subgroup analysis of the ALTER0303 trial

From: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

EGFR status

Median OS (months)

HR (95% CI)

P value

Placebo arm

Anlotinib arm

Wild-type

6.47

8.87

0.73 (0.55–0.97)

0.022

Sensitive mutationsa

6.27

10.70

0.59 (0.38–0.94)

0.023

  1. EGFR, epidermal growth factor receptor; OS, overall survival; HR, hazard ratio
  2. aSensitive mutations include exon 19 deletion and exon 21 Leu858Arg
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us